MAPT and Alzheimer disease: It is possible that heterogeneity in clinical trial data in AD may be because under the age of 65 years AD is driven by amyloid, whereas over 65 years amyloid may be part of protective neurochemical reaction to AD pathology, tau and other factors may be more operational.